S. Kronborg-White (Lystrup, Denmark), G. Margaritopoulos (London, United Kingdom)
Clinical characteristics of anti-Jo-1-positive interstitial lung disease
S. Chang (Seoul, Republic of Korea), M. Shin (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea)
|   |
Health-related quality of life in children interstitial lung disease
N. Nathan (Paris, France), C. Lauby (Paris, France), R. Abou Taam (Paris, France), K. Bessaci (Reims, France), J. Brouard (Caen, France), M. Dalphin (Besançon, France), C. Delacourt (Paris, France), C. Delestrain (Paris, France), A. Deschildre (Lille, France), J. Dubus (Marseille, France), M. Fayon (Bordeaux, France), L. Giovannini-Chami (Nice, France), V. Houdouin (Paris, France), A. Houzel (Dijon, France), C. Marguet (Rouen, France), I. Pin (Grenoble, France), P. Reix (Lyon, France), M. Renoux (Montpellier, France), C. Schweitzer (Nancy, France), A. Tatopoulos (Nancy, France), C. Thumerelle (Lille, France), F. Troussier (Angers, France), S. Wanin (Paris, France), L. Weiss (Strasbourg, France), A. Clement (Paris, France), P. Boelle (Paris, France), R. Epaud (Créteil, France)
| |
Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network
M. Kreuter (Heidelberg, Germany), F. Bonella (Essen, Germany), N. Blank (Heidelberg, Germany), E. Siegert (Berlin, Germany), J. Henes (Tuebingen, Germany), M. Worm (Berlin, Germany), C. Sunderkoetter (Muenster, Germany), M. Schmalzing (Wuerzburg, Germany), A. Kreuter (Oberhausen, Germany), C. Guenther (Dresden, Germany), L. Susok (Bochum, Germany), G. Zeidler (Treuenbrietzen, Germany), I. Koetter (Hamburg, Germany), U. Mueller-Ladner (Bad Nauheim, Germany), T. Krieg (Cologne, Germany), A. Juche (Berlin, Germany), T. Schmeiser (Wuppertal, Germany), G. Riemekasten (Luebeck, Germany), E. Aberer (Graz, Austria), N. Gaebelein-Wissing (Wuppertal, Germany), J. Distler (Erlangen, Germany), M. Sárdy (Munich, Germany), C. Pfeiffer (Ulm, Germany), K. Kuhr (Cologne, Germany), H. Lorenz (Heidelberg, Germany), P. Moinzadeh (Cologne, Germany), N. Hunzelmann (Cologne, Germany)
| |
Death in ILD - Why arent we talking about it?
A. Hudson (London, United Kingdom), A. Hare (London, United Kingdom), L. Berry (London, United Kingdom), L. Freeman (London, United Kingdom), P. George (London, United Kingdom)
| |
Factors associated with increased arterial stiffness in patients with chronic hypersensitivity pneumonitis
E. Leonova (Moscow, Russian Federation), E. Shmelev (Moscow, Russian Federation)
| |
Childhood Interstitial Lung disease: A Tertiary Single Center Experience
T. Ramasli Gursoy (Ankara, Turkey), A. Aslan (Ankara, Turkey), Z. Onay (Ankara, Turkey), T. Sismanlar Eyuboglu (Ankara, Turkey)
| |
Utility of myositis related antibodies in interstitial lung disease and suspected autoimmunity.
M. Florenzano (Santiago, Chile), J. Maya (Santiago, Chile), F. Reyes (Santiago, Chile), C. Cuellar (Santiago, Chile), A. Peralta (Santiago, Chile), V. Balboa (Santiago, Chile), L. Toro (Santiago, Chile), V. Wolff (Santiago, Chile)
| |
Prognostic factors in patients with EAA
P. Sojka (Prague, Czech Republic), M. Šterclová (Prague, Czech Republic), N. Kaspríková (Prague, Czech Republic), M. Vašáková (Prague, Czech Republic)
| |
Utility of inhalation challenge test using avian egg for hypersensitivity pneumonia
R. Okuda (Yokohama, Japan), T. Katano (Yokohama, Japan), M. Asaoka (Yokohama, Japan), Y. Uchida (Yokohama, Japan), S. Ikeda (Yokohama, Japan), R. Ootoshi (Yokohama, Japan), E. Tabata (Yokohama, Japan), R. Shintani (Yokohama, Japan), H. Okabayashi (Yokohama, Japan), T. Niwa (Yokohama, Japan), T. Oda (Yokohama, Japan), A. Sekine (Yokohama, Japan), H. Kitamura (Yokohama, Japan), T. Baba (Yokohama, Japan), S. Komatsu (Yokohama, Japan), E. Hagiwara (Yokohama, Japan), T. Ogura (Yokohama, Japan)
| |
Biomarkers in peripheral blood from patients with chronic silicosis caused by artificial quartz agglomerates
A. Leon Jimenez (Cádiz, Spain), G. Jiménez Gómez (Cádiz, Spain), A. Hidalgo Molina (Cádiz, Spain), A. Córdoba Doña (Cádiz, Spain), A. Campos Caro (Cádiz, Spain)
| |
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
G. Raghu (Seattle, United States of America), O. Distler (Zurich, Switzerland), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), M. Mayes (Houston, Texas, United States of America), D. Wachtlin (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), T. Maher (London , United Kingdom)
| |
Variables associated with functional improvement in patients with interstitial lung disease and myositis related antibodies: Results from a multicentric Latin American study.
M. Alberti (Buenos Aires, Argentina), V. Wolff (Santiago de Chile, Chile), F. Reyes (Santiago de Chile, Chile), E. Juarez Leon (Mexico DF, Mexico), V. Leiva (Santiago de Chile, Chile), G. Carballo (Buenos Aires, Argentina), J. Rojas Serrano (Mexico DF, Mexico), M. Mejía (Mexico DF, Mexico), L. Fassola (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina), M. Florenzano (Santiago de Chile, Chile), F. Paulin (Buenos Aires, Argentina)
| |
Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis
A. Hoffmann-Vold (Oslo, Norway), T. Maher (London, United Kingdom), E. Philpot (Durham, NC, United States of America), A. Ashrafzadeh (San Diego, CA, United States of America), O. Distler (Zurich, Switzerland), M. Kreuter (Heidelberg, Germany)
| |
Nocturnal desaturation predicts mortality in immune-mediated ILDs
G. Margaritopoulos (London, United Kingdom), A. Proklou (Heraklio, Greece), D. Badenes Bonet (Barcelona, Spain), F. Chua (London, United Kingdom), P. George (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Kouranos (London, United Kingdom), E. Renzoni (London, United Kingdom), K. Antoniou (Heraklio, Greece), A. Wells (London, United Kingdom)
| |
Verification of genetic associations with Scleroderma associated Interstitial Lung Disease
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), V. Ong (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)
| |
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), V. Ong (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)
| |
Effect of photobiomodulation on inflammation and production of TGF-ß in experimental model of pulmonary fibrosis.
A. De Brito Léia (São Paulo, Brazil), K. Herculano (São Paulo, Brazil), T. Santos (São Paulo, Brazil), N. Rigonato-Oliveira (São Paulo, Brazil), C. Alves (São Paulo, Brazil), R. Palma (BARCELONA, Spain), C. Alvarenga-Nascimento (São Paulo, Brazil), A. Ligeiro-Oliveira (São Paulo, Brazil)
| |